Chandramohan D, et al. – Researchers assessed 19,578 African children (3 to 59 months of age) randomized to receive seasonal malaria chemoprevention plus either azithromycin (9735 children) or placebo (9843 children) to determine the effects of azithromycin when added to the monthly sulfadoxine-pyrimethamine plus amodiaquine (used for seasonal malaria chemoprevention) on mortality and morbidity. The azithromycin and placebo groups had similar prevalences of malaria parasitemia and incidences of adverse events. No lower incidence of death or hospital admission was observed with the addition of azithromycin to the antimalarial agents that was not due to trauma or surgery than antimalarial agents plus placebo, although they noted a lower disease burden with azithromycin vs placebo.